Invenra and the Wisconsin Alumni Research Foundation have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, the company announced recently.

“This collaboration is a good example of the benefits that can come from partnerships between the UW-Madison and industry,” Invenra CEO Roland Green said in a statement. “We are very excited about this program and the potential it has for helping these children with neuroblastoma.”

According to a release, the collaboration will use Invenra’s proprietary SNIPER technology to allow for precise targeting of the cancer cells while sparing normal nerve cells and potentially alleviating unwanted toxicities and pain-related side effects.

Neuroblastoma is the third-most common childhood cancer.